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Background: Long acting injections (LAI) have been associated with perceptions of coercion in cross sectional studies
but there have been no longitudinal studies of the effects on clinical relationships with newer depot medications.
Method: Randomized controlled trial with (50) participants with a diagnosis of schizophrenia randomized to risperidone
LAI or oral atypical antipsychotic medication. The main outcome was the Working Alliance Inventory (WAI) with
background variables (symptoms, side effect, social functioning, quality of life) measured before randomization and at
two years.
Results: At follow-up (14 risperidone LAI and 16 oral medication) analyses including predictors of missing data and
baseline score showed a trend for those on risperidone LAI to reduce WAI score and those on oral medication showing
no change. Sensitivity analyses showed (i) a significant detrimental effect of LAI on WAI and (ii) the pattern of results was
not affected by change in symptoms over the study.
Conclusion: This is the first study to show that the prescription of depot atypical depot medication is associated with
detrimental effects on clinical relationships after 2 years of continual treatment.
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Working alliance is the name given to the therapeutic rela-
tionship between a clinician and a patient. A good thera-
peutic relationship between clinician and patient is
purported to be vital for a good outcome [1] and across all
psychiatric disorders there is good supporting evidence
that working alliance is a significant predictor of broad
based outcomes which is not moderated by the severity of
the psychiatric disorder [2,3]. Working alliance refers to
the relationship between the clinician and the patient on
such issues as goals and means of achieving goals.
In people with a diagnosis of schizophrenia, thera-
peutic alliance predicts successful outcome from cogni-
tive behavioural therapy [4,5]. Poorer working alliance* Correspondence: til.wykes@kcl.ac.uk
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reproduction in any medium, provided the orhas been found to be related to increased symptom se-
verity and, in some studies, reduced social ability [6-9].
Evidence for long acting injectable (LAI) or depot
medication affecting the therapeutic relationships is
mixed. Some patients perceive long-acting depot anti-
psychotics to be coercive [10,11] while many clini-
cians maintain that depots are underutilized as they
offer advantages in terms of convenience, enhanced
relapse prevention with reduced rehospitalization
rates [12-15]. Intriguingly in a recent meta-analysis of
oral versus depot medication studies, Leucht and col-
leagues showed that relapse was reduced for people
on depot medication although oral medication non-
adherence was rated as no greater than with depot. It
may be that clinicians are over-estimating adherence
in those on oral medication compared to depot where
compliance is easily monitored.
The ability to monitor medication compliance may
fuel patients' negative attitudes to medication. For in-
stance, Patel and colleagues [16] found that patients’Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion, including the experience of coercion [17], was
related to perceptions of being forced to take medi-
cation. These authors suggest that perceived coercion
might be alleviated if the decision on prescribing is
discussed using non-threatening language and with
respect given to patient’s illness beliefs. Proper atten-
tion should also be given to patient choice. However,
it should be noted that the patients in that and prior
studies would have had all or most of their experi-
ence with first generation ‘typical’ depots which are
likely to have more extra-pyramidal side effects than
second generation or ‘atypical’ antipsychotics.
The study here investigates whether being placed on
long acting atypical antipsychotic medication leads to
worsening of the therapeutic alliance, as measured using
the Working Alliance Inventory (WAI), in relation to
oral atypical antipsychotic medication. This was a multi-
centre, multi country, industry-sponsored clinical trial.
The UK arm was hosted in the National Health Service
(NHS) by infrastructure called the National Institute for
Health Research (NIHR) Mental Health Research Net-
work (MHRN) [18]. The industry partner agreed to in-
clude a service user valued outcome in addition to the
main (illness exacerbation) and secondary outcomes in
their protocol, namely a measure of therapeutic alliance.
The aim of this add-on study was to investigate whether
effects on the relationship between clinician and patient
depended on the trial arm.
In this RCT, the participants knew that they were
entering a study where the treatment decision would
be made by the randomization programme. While
they must have accepted in principle that they may be
placed in the long acting injection arm, as part of the
informed consent process of the trial, the actual deci-
sion to do so would have been made independently.
Thus the effect of having a LAI on the therapeutic al-
liance can be studied prospectively in relative isolation
of other clinical factors. The study benefits signifi-
cantly from a randomized design which controls for
any factors that would normally be associated with
clinicians and patients reaching a consensus about
commencing depot treatment. The current study also
has the advantage of comparing LAI and oral atypical
agents thus matching broadly for the range of likely
side effects. Finally, because severity of distress influ-
ences ratings on the WAI we also report associations
between the scale and a range of standard measures
of symptoms, illness severity and level of functioning
fundamental to psychotic disorders.
Aims
To assess whether the experience of atypical LAI is asso-
ciated with changes in clinical alliance.Method
Design
Data for this paper were drawn from a randomized,
open-label, parallel-group, multi-country and multi-
centre study of risperidone LAI versus oral atypical anti-
psychotics (AAP). Only data from the UK are included
here as this centre only collected measures of thera-
peutic alliance. Assessments used in these analyses are
taken from the baseline and final outcomes which is
when the therapeutic alliance was measured. In between
these assessments there were four other assessment
points when clinical exacerbations were measured. The
design was posted on ClinicalTrials.gov, NCT00256997;
sponsor Janssen-Ortho Inc., Canada.
Ethics
The study complied with the Helsinki Declaration
(http://www.wma.net/en/30publications/10policies/b3/
index.html). Research Ethics Committees of Northern
Ireland (ORECNI) Ref number 05/NIR05/41.
Participants
Detailed entry criteria are shown on the registered trial
protocol. The ones of relevance in this study are:
• DSM-IV TR diagnosis of schizophrenia.
• currently treated with oral AAP medication.
• aged 18 – 65 years.
• have had at least 2 hospitalisations or clinical
exacerbations over the past 2 years due to suspected
poor adherence.
• non-treatment resistance shown by a satisfactory
response to oral antipsychotics.
All participants gave written informed consent.
Measures and procedure
All measures were collected independently of clinical
teams by trained researchers who interviewed partici-
pants or who collated the self report data.
(i) Main outcome of interest - Therapeutic Alliance:
Working Alliance Inventory:
Working Alliance Inventory (WAI [19]); is a 36-item
self report measure completed by all participants
about their relationship with their prescribing
psychiatrist. Each item is measured on a seven point
scale of −3 to +3. Higher scores indicate better
working alliances. Cronbach’s alpha for this client
completed scale is reported as 0.93 and for items in
the current smaller sample was 0.79.(ii) Symptoms:
Positive and Negative Symptom Scale (PANSS;
[20]) divided into Positive, Negative, General and
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Severity (CGI-S; [21]) which is a 7 point scale
(1 = mild symptom levels, 7 extremely severe)
and Clinical Global Impression Change (CGI-C)
which is also a 7 point scale (1 = much
improved, 7 = very much worse).(iii)Quality of life:
Assessment of Quality of Life (AQoL; [22])
measures five dimensions; illness, independent
living, social relationships, physical senses and
psychological wellbeing. Cronbach’s alpha 0.81 for
the whole scale.(iv) Functioning:
Personal and Social Performance Scale (PSP; [23])
The PSP is a 100-point single-item rating scale,
subdivided into 10 equal intervals. The scale covers
four main areas: socially useful activities, personal
and social relationships, self-care and disturbing
and aggressive behaviours.(vi) Clinical Exacerbations:
These are defined as one of the following:
• Hospitalization due to an exacerbation of
participant's schizophrenia.
• A change from current antipsychotic or initiation
of an adjunctive antipsychotic treatment.
• a 2-point worsening in CGI-S plus at least one of
the following (emergency or exceptional treatment
as a result of clinical exacerbation, increased dose
of medication as a result of poor symptom control,
deliberate self-injury or emergence of clinically
significant suicidal or homicidal ideation, violent
behaviour resulting in injury or property damage).Statistical analyses
(i) Missing data: If scale items for WAI were not
complete then we prorated the scores as long as
more than 80% of items had been completed.
The assumption that participants were missing
at random was investigated using univariate
logistic regression analyses using demographic
predictors which were then included in the
longitudinal analyses otherwise we assumed that
a complete case analysis is appropriate. For
some analyses missing data at baseline was
replaced by total sample mean and at follow-up
the mean overall baseline WAI scores pre-
randomization was used in the imputation.
Methods of imputation were investigated in
sensitivity analyses.
(ii) Baseline relationships between symptoms, quality
of life and social functioning were explored using
correlations.(iii) Changes in WAI over time were investigated using
paired t-tests and the effect of trial arm on WAI
change using ANCOVA with baseline WAI as one
covariate. As the relationship between clinician and
patient is likely to be affected by clinical change
over time we included whether a clinical
exacerbation had occurred after 12 weeks (i.e. after
a stable dose of medication had been achieved) as a
further covariate in all analyses. Any predictor of
missingness was also included in the model.
All analyses were carried out using STATA 11.2
(StataCorp).
Results
54 participants were recruited to the study but 4
dropped out or were withdrawn prior to the baseline as-
sessment and prior to randomization leaving 50 people
who completed WAI at baseline. After pro-rating, 2 par-
ticipants were not scored because they failed to
complete >80% of the items, leaving 48 participants. At
follow-up 30 people completed enough of the WAI
items (i.e. above 29) to achieve a WAI score (14 risperi-
done LAI and 16 oral medication group). The socio-
demographic and clinical characteristics of the participants
at baseline are shown in Table 1. The groups, as expected
from randomization, were relatively well balanced although
the depot group were slightly younger than the oral medi-
cation group (36.9 vs 42.6) but this was not a significant
difference (Table 1).
The participants were mostly men, of white origin
who were middle aged which is representative of those
who have had some long term treatment which has not
been particularly effective. They also had moderately se-
vere symptoms and marked social and personal difficul-
ties which were correlated (r = −0.56, p < 0.001).
Despite the possible barriers to a good therapeutic alli-
ance (poor social functioning and higher levels of symp-
toms) the majority of WAI scores were positive which
indicates a good working relationship. Only two indivi-
duals at baseline indicated that it was poor. Given that
this group of participants would have been selected by
their clinical teams as being potentially interested in tak-
ing part in a trial, it is likely that part of the judgement
of potential participation was based on the quality of the
therapeutic relationship.
Baseline assessments
Identification of predictors of missingness
Potential specific predictors (Trial arm and baseline
WAI) were explored and neither showed a significant ef-
fect. At follow-up 11 participants from risperidone LAI
and 7 from the oral trial arm were missing (χ2 (1) = 0.94,
p = 0.33) and baseline WAI was explored in a regression
Table 1 Sample characteristics, main outcome and background variables; Average, [proportion] standard deviation
Risperidone LAI Group n = 26 Oral Medication Group n = 24 Total group n = 50
Demographic variables
Age, years 36.8 (10.81) 42.58 (10.71) 39.6 (11.04)
Gender 73% Male, 70% Male 72% Male,
Ethnicity 77% White, 54% White, 66% White,
Substance use/abuse 46% No, 58% No 52% No,
Clinical symptoms
Median (IQR) Median (IQR) Total Group
Baseline Follow-up Baseline Follow-up Baseline
PANSS total 80 (67–91) 71.5 (51–88) 71 (62.5-86) 60 (41–86) 80 (65–90)
PANSS Positive 16.5 (14–26) 15.5 (12–22) 17 (13–21) 15 (10–21) 18 (13–22)
PANSS Negative 21 (14–25) 17 (13–21) 20 (17.5-25) 16 (11–22) 21.5 (17–27)
CGI-Severity 4.5 (4–5) 3.5 (3–5) 4 (3–5) 3 (2–4) 4 (3–5)
AIMS 0 (0–1) 0 (0–0) 1 (0–3.5) 0 (0–1) 0 (0–3)
Quality of life
AQOL Illness 0.42 (0.17-0.52) 0.52 (0.42-0.64) 0.36 (0.14-0.59) 0.42 (0.26-0.53) 0.40 (0.15-0.52)
AQOL Activities Daily Life 0.78 (0.62-0.0.86) 0.88 (0.78-1.00) 1.00 (0.78-1.00) 1.00 (0.79-1.00) 0.79 (0.62-1.00)
AQOL Social 0.70 (0.27-0.82) 0.74 (0.35-0.88) 0.69 (0.24-0.88) 0.74 (0.35-0.94) 0.69 (0.24-0.83)
AQOL Physical 1.00 (0.82-1.00) 0.93 (0.82-1.00) 1.00 (0.94-1.00) 1.00 (0.94-1.00) 1.00 (0.88-1.00)
AQOL Psychological 0.87 (0.73-0.91) 0.91 (0.73-0.93) 0.87 (0.67-0.93) 0.95 (0.83-1.00) 0.87 (0.70-0.93)
Mean (sd) Mean (sd) Mean (sd) Mean (sd) Mean (sd)
Working Alliance (prorated) 48.33 (33.10) 27.30 (27.90) 45.97 (31.64) 49.30 (35.32) 48.20 (32.08)
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Exacerbations at 12 weeks which was intended as a
covariate was a significant predictor of missing out-
come measure at follow up (χ2 (1) = 4.16, p = 0.041)
and was retained as a covariate. No other patient measures
(including demographic (age, gender, ethnicity) clinical sta-
tus (PANSS, CGI, AIMS, PSP) or Quality of Life (AQOL
subscales)) were significantly associated with missing data
at follow up.
Are there relationships between clinical variables and
clinical alliance?
No demographic variables were related to baseline WAI
scores (n = 48). Given previous research it might be
expected that poorer social functioning and worse symp-
toms would be related to working alliance but in these
analyses there was only a significant correlation with
total symptoms (total PANSS score r = −0.29 p = 0.046,
n = 48); more symptoms, poorer working alliance. How-
ever, people with substance misuse had similar WAI
scores to those who had no current substance misuse. In
terms of aspects of quality of life, the only significant
correlation with baseline WAI score was level of per-
ceived physical problems (correlation r = 0.36, p = 0.013).
Changes over time
The presence of clinical exacerbations 12 weeks from treat-
ment onset did not differ between those who completedtherapy and completed the WAI (Risperidone LAI = 4, oral
AAP = 3; Fisher’s Exact test p = 0.6).
The first longitudinal analysis showed no significant
change of WAI over time (N = 30, baseline WAI = 43.2
(sd31), follow-up WAI 39.0 (sd 33) paired t = 0.73, df 29,
p = 0.47). This result is unlike that for most other clinical
variables which did improve over time either signifi-
cantly or at a trend level. All were tested using Wilcoxon
sign-rank test due to non-normality: Symptoms (N = 42,
z = 2.34, p = 0.019) CGI (N = 43, z = 3.03, p = 0.003), side
effects (AIMS N = 40 z = 2.49, p = 0.013); Quality of Life
illness (N = 36, z = −2.12, p = 0.034) and Quality of Life
activities of daily living (N = 36, z = −2.82, p = 0.005).
The only variable not showing this pattern was social
and personal functioning which showed no change (PSP
N = 43 z = −1.08, p = 0.279). There were no relationships
between symptom changes and WAI and no effect of
trial arm on these clinical and quality of life measures.
The second set of analyses concentrated on testing
whether the treatment arm affected follow-up scores
on WAI. The analyses of WAI change over time
included only complete cases and after prorating of
scores there were 30 participants remaining (risperi-
done LAI 14, oral medication 16). In the ANCOVA
WAI score at follow-up was the dependent variable,
treatment group was the independent variable and
baseline WAI and presence of an exacerbation were
covariates in a linear regression model with robust
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ment group effect (Treatment group coefficient =
19.29, p = 0.076, 95% CI −2.20 to 40.78). The effect is
illustrated in Figure 1. For the risperidone LAI group
working alliance reduces over the trial whereas the
oral group does not change. In the model baseline
WAI was significant (coefficient = 0.55, p = 0.006, 95%
CI 0.18 to 0.94) but exacerbations after 12 weeks
was not.
We also carried out a sensitivity analysis to include all
participants under the assumption that missing follow up
data would be the average baseline WAI score. This sample
contained 2 participants whose baseline scores were miss-
ing (one per trial arm) so these were also imputed as the
baseline WAI score. In this model (N = 50) the effect of
trial arm was significant (coefficient 13.66, p = 0.048, 95%
CI 0.13 to 27.19) with WAI falling in the LAI group. Again
baseline WAI was significant (coefficient = 0.34, p = 0.006,
95% CI 0.10 to 0.58) and exacerbations at 12 weeks and
the missing follow up indicator were not.
A further sensitivity analysis that adjusted for change
in PANSS score from baseline to follow up was per-
formed on the model conducted for the primary ana-
lysis i.e. regression of WAI score at follow up on trial
arm, exacerbations at 12 weeks, baseline WAI score
and PANSS change from baseline as covariates (N = 30).
This further analysis was to adjust for any change in
symptoms throughout the study that may have an effect
on the working alliance. When this was entered into
the model the same pattern of results remained - trend for
an effect of treatment on change in WAI (coefficient =
19.58, p = 0.074, 95% CI −2.01 to 41.18). In this model
baseline WAI was significant (coefficient = −0.19, p = 0.007,
95% CI 0.16-0.23) but exacerbations after 12 weeks and

















Figure 1 Predicted mean WAI scores at time 2 from the regression m
baseline WAI scores.Discussion
The study was unusual in that participants were taking
part in a trial that would test the effectiveness of differ-
ent drug formulations over a two year period. Most
studies only follow participants up for relatively short
periods of time and so do not uncover possible changes
in service user valued outcomes. It is assumed that
working alliance develops over a period of time and as
such any changes will only be detected over periods of
longer than one year. This trial offered an opportunity
to investigate such changes. The participants entering
the study had been in touch with their clinical teams for
some time and already had a reasonably good thera-
peutic relationship. It is likely that it was this good rela-
tionship that led individuals to feel they would consent
to the study. But it also suggests that it might be difficult
to lift the level further.
In our study therapeutic relationship at baseline was
related to symptom severity which has been reported
previously [6-9]. This same pattern of relationships was
also found at the end of the trial suggesting it is robust
to changes in symptom level (r = −.443, df 1, p = 0.016).
But unlike other studies we did not find a relationship
with social functioning although previous evidence of
such a relationship has not been consistent. This might
be because of differences in measurement or the fact
that social functioning in this group has little variation
making subtle effects difficult to identify.
Is there an effect of trial arm on therapeutic alliance?
All the clinical indices measured in this study improved
over the course of the study but the trial arms could not
be distinguished on these measures.
Working Alliance did show a trend for a treatment ef-
fect in the complete case analysis and this trend became2
epoint
 LAI 95% CI
95% CI
odel after adjusting for trial arm, exacerbations at 12 weeks and
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decrease in WAI only in the risperidone LAI arm of the
trial. There were no changes in the oral arm. This is des-
pite changes over time favouring improvements in the
two groups.
Poorer working alliance being related to receiving
depot medication is assumed because most data on
depot medication show higher feelings of coercion which
is not consistent with a good therapeutic relationship
[10,11]. However, all this evidence comes from cross sec-
tional studies investigating groups who have often
received depot medication for some time. The difference
in this study is that for the first time working alliance
was measured directly and not inferred from coercion
data. In addition, this is the first time that an investiga-
tion was carried out as individuals change from one oral
medication to a depot. The fact that patients receiving
depot medication perceive a loss of therapeutic relation-
ship is certainly important clinically. It may be that
depot medication has positive outcomes clinically, al-
though in our study we could not distinguish the groups
on symptoms or side effects, but decreases in clinical al-
liance might counteract these clinical gains in terms of
translating them into real life functioning outcomes. Un-
fortunately perceived coercion was not measured in this
study so we cannot say that this mediates (or is
mediated by) a change in working alliance.
A good working alliance can be regarded as positive in
and of itself as well as being a vehicle for aiding service
users to follow treatment protocols (see [24]). In our
study the trend for a reduction in working alliance asso-
ciated with depot medication would not have had the
latter effect since missing an injection would have been
interpreted as a study violation and essentially drop-out.
However, it may lead to reductions in compliance with
other helpful treatment protocols such as recovery pro-
grammes or psychological treatments. This is a topic for
future research.
Strengths and limitations
A strength of the study is its longitudinal design and
randomized treatment arms which provide methodo-
logical rigour. Previous studies of patients attitudes to-
wards depots have often been cross sectional and
because of a lack of randomization are limited by medi-
cation decisions being based on medical need. We also
had a long period over which to assess an outcome
which is likely to take months to develop and change.
However, many patients considered for LAI will not
have been able or willing to participate in an RCT de-
sign, because of comorbidities, instability or perhaps a
very poor therapeutic alliance with their clinical teams,
hence the generalizability of the study may be limited.
The sample was mainly male and Caucasian which limitsgeneralizability. There is a loss of statistical power
through missing follow-up data resulting from such long
follow-up. So in order to be rigorous we not only inves-
tigated missingness thoroughly but we also tested our
assumptions, included any predictors of missingness and
carried out sensitivity analyses. Our imputation model
did show a significant effect and this result fits with
other data on feelings of coercion experienced by people
with psychosis who are prescribed depot medications.
The worldwide study was terminated early because of
very slow recruitment in some sites but we do not feel
this was a limitation for this analysis as recruitment rates
were reasonable in the UK. Clearly had we been able to
continue recruitment a larger sample would have
allowed more subtle effects to be detected and, of
course, provide more substantive support for our find-
ing. Finally the study did not record details of the thera-
peutic relationship and factors such as the number of
face-to-face contacts and duration. Such factors may be
important mediators of the WAI in this patient group.
We would not have been able to carry out this study
without the vehicle of a randomized control trial spon-
sored by industry. The model of using current large scale
Phase 3 or 4 studies to provide outcomes of import-
ance to industry in addition to those of more academic
or clinical interest provides for a clear future research
partnership. In this study the company invested in an
add-on study of specific interest to service users from
the public and patient involvement arm of NIHR
MHRN. This meant that the study was more appealing
to both clinicians and service user alike and gave it
even more clinical relevance. The NHS infrastructure
provided by NIHR foster these partnerships with their
high quality delivery mechanisms and well formed ser-
vice user involvement.
Conclusions
The study reports that there is a reduction in working
alliance following the introduction of an LAI compared
to continuing on oral medication. This is despite the
clinical benefits achieved by both groups of patients.
There are other important mediators and moderators
that were not investigated but could provide clear advice
on how to avert such effects.
Clinical implications
The results of this longitudinal study suggest that pos-
sible deterioration of working alliance needs further at-
tention when a patient has been prescribed a depot even
when they participated in the decision making (i.e.
agreement to participate in the trial). Mental health staff
should also ensure that prescription of a depot is a true
choice for the service user. The study design allows us
to conclude that the prescription of an LAI is most likely
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and this is a strong argument for service user choice.
Therapeutic relationships may also vary with the mo-
dality of medication in the sense that more attention
is given by clinicians to those on oral medication to
ensure adherence. For those on depot the contact
may be limited to visits to specialised clinics where
less time is spent on continued development of the
therapeutic relationship. Future studies need to con-
centrate on whether improving the therapeutic rela-
tionship can of itself alleviate the negative effects of
receiving LAIs found in this investigation.
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